New drug cocktail aims to stop deadly blood cancer before it starts
NCT ID NCT06100237
First seen Feb 24, 2026 · Last updated Apr 16, 2026 · Updated 5 times
Summary
This study is testing whether two different drug combinations can delay or prevent the development of full-blown multiple myeloma in people with high-risk early-stage disease. Researchers will enroll 50 adults with smoldering myeloma to receive either teclistamab with daratumumab or talquetamab with daratumumab. The main goal is to see if these treatments can eliminate detectable cancer cells and prevent progression to symptomatic disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.